A Tel Aviv University (TAU) study suggests a new target for Alzheimer's (lat. morbus Alzheimerianus) research: the APOE gene. This gene has two faces: a healthy form called APOE3 and a disease-related pathological form called APOE4. Researchers have developed a novel mechanism and approach with which to convert the 'bad' APOE4 to the 'good' APOE3. The research was led by Prof. Daniel M. Michaelson, Director of the Eichenbaum Laboratory of Alzheimer's Disease Research and incumbent of the Myriam Lebach Chair in Molecular Neurodegeneration at TAU's Faculty of Life Sciences, together with Anat Boehm-Cagan, the Eleanore and Harold Foonberg Doctoral Fellow in Alzheimers Disease Research, and in collaboration with the commercial company Artery Ltd., based in California.